CandlesenseCandlesense
NVCT•benzinga•

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Summary

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 14, 2024 by benzinga

← Back to NVCT News
    Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug | NVCT Stock News | Candlesense